The role of ursodeoxycholic acid in the treatment of hepatobiliary diseases in children
DOI:
https://doi.org/10.15574/SP.2022.125.84Keywords:
ursodeoxycholic acid, primary biliary cholangitis, cholestasis, biliary dysfunction, drug-induced liver disease, hepatoprotector, gallstone diseaseAbstract
It is a well-known that a significant part in the structure of the digestive system diseases in children compounds disorders of the biliary tract, which are based on violations of the regulation of bile production and bile secretion.
The topical issue is the search for safe and effective drugs that can prevent the transformation of biliary disorders into organic pathology, including cholecystitis, gallstone disease. One of such drugs is ursodeoxycholic acid (UDCA), which is actively use in pediatrics due to its hepatoprotective, immunomodulatory, choleretic, anticholestatic and other properties.
The results of the literature review indicate that UDCA therapy provides various clinical effects: it improves liver function by lowering the level of liver enzymes, prevents the progression of liver diseases. In addition, its influence on the transformation of functional changes into organic pathology, especially in patients with diseases of the hepatobiliary tract associate with cholestasis, and is an alternative option for the treatment of chronic liver disease.
Proven therapeutic efficacy, high quality and safety of UDCA create the prospect of including this drug in the treatment of children with functional and organic diseases of the liver and biliary tract.
No conflict of interests was declared by the authors.
References
Abaturov AE. (2017). Vlyianye ursodezoksykholevoi kysloty na ekspressyiu mykro-RNK pry zabolevanyiakh bylyarnoi systemy u detei. Zdorovia Ukrainy. Tematychnyi nomer «Pediatriia». 4: 3-3.
Abdulrab S, Al-Maweri S, Halboub E. (2020). Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm. Medical Hypotheses. 143: 109897. https://doi.org/10.1016/j.mehy.2020.109897; PMid:32505909 PMCid:PMC7261102
Andrade RJ, Chalasani N, Björnsson ES, Suzuki A, Kullak-Ublick GA et al. (2019). Drug-induced liver injury. Nature Reviews Disease Primers. 5 (1): 1-22. https://doi.org/10.1038/s41572-019-0105-0; PMid:31439850
Antypkin YuH, Volosovets OP, Maidannyk VH, Berezenko VS, Moiseienko RO et al. (2018). Stan zdorovia dytiachoho naselennia - maibutnie krainy. Zdorove rebenka. 1: 1-11.
Bordbar M, Shakibazad N, Fattahi M, Haghpanah S, Honar N. (2018). Effect of ursodeoxycholic acid and vitamin E in the prevention of liver injury from methotrexate in pediatric leukemia. The Turkish Journal of Gastroenterology. 29 (2): 203. https://doi.org/10.5152/tjg.2018.17521; PMid:29749328 PMCid:PMC6284693
Chascsa D, Carey EJ, Lindor KD. (2017, Apr). Old and new treatments for primary biliary cholangitis. Liver Int. 37 (4): 490-499. https://doi.org/10.1111/liv.13294; PMid:28371104
Cheng K, Ashby D, Smyth RL. (2017). Ursodeoxycholic acid for cystic fibrosis‐related liver disease. Cochrane Database of Systematic Reviews: 9. https://doi.org/10.1002/14651858.CD000222.pub4; PMid:28891588 PMCid:PMC6483662
Chernobrovyi VM, Melashchenko SH. (2014). Ursodezoksykholeva kyslota: klinichna praktyka (mynule ta sohodennia). Suchasna hastroenterolohiia. 1: 99-109.
Colombo C, Alicandro G, Oliver M, Lewindon PJ, Ramm GA et al. (2022). Ursodeoxycholic acid and liver disease associated with cystic fibrosis: A multicenter cohort study. Journal of Cystic Fibrosis. 21 (2): 220-226. https://doi.org/10.1016/j.jcf.2021.03.014; PMid:33814323
Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. (2000). The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology. 32 (6): 1196-1199. https://doi.org/10.1053/jhep.2000.20240; PMid:11093724
Daruich A, Jaworski T, Henry H, Zola M, Youale J et al. (2021). Oral Ursodeoxycholic Acid Crosses the Blood Retinal Barrier in Patients with Retinal Detachment and Protects Against Retinal Degeneration in an Ex Vivo Model. Neurotherapeutics. 18 (2): 1325-1338. https://doi.org/10.1007/s13311-021-01009-6; PMid:33537951 PMCid:PMC8423962
Deneau M, Perito E, Ricciuto A, Gupta N, Kamath BM et al. (2019). Ursodeoxycholic acid therapy in pediatric primary sclerosing cholangitis: predictors of gamma glutamyltransferase normalization and favorable clinical course. The Journal of pediatrics: 209: 92-96. https://doi.org/10.1016/j.jpeds.2019.01.039; PMid:30878206 PMCid:PMC6535363
Enright EF, Griffin BT, Gahan CG, Joyce SA. (2018). Microbiome-mediated bile acid modification: role in intestinal drug absorption and metabolism. Pharmacological Research. 133: 170-186. https://doi.org/10.1016/j.phrs.2018.04.009; PMid:29660405
European Association for the Study of the Liver. (2017). EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. Journal of hepatology. 67 (1): 145-172. https://doi.org/10.1016/j.jhep.2017.03.022; PMid:28427765
Food and Drug Administration. (2016). Summary minutes of the Gastrointestinal Drugs Advisory Committee (GIDAC). URL: http://www.sefap.it/farmacovigilanza_news_201102/UCM242264.pdf.
Gelsomino F, Vitale G, D'Errico A, Bertuzzi C, Andreone P, Ardizzoni A. (2017). Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Annals of Oncology. 28 (3): 671-672. https://doi.org/10.1093/annonc/mdw649; PMid:27993797
Guarino MPL, Cocca S, Altomare A, Emerenziani S, Cicala M. (2013). Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed. World Journal of Gastroenterology: WJG. 19 (31): 5029. https://doi.org/10.3748/wjg.v19.i31.5029; PMid:23964136 PMCid:PMC3746374
Hanafi NI, Mohamed AS, Sheikh Abdul Kadir SH, Othman MHD. (2018). Overview of bile acids signaling and perspective on the signal of ursodeoxycholic acid, the most hydrophilic bile acid, in the heart. Biomolecules. 8 (4): 159. https://doi.org/10.3390/biom8040159; PMid:30486474 PMCid:PMC6316857
Harms MH, van Buuren HR, Corpechot C, Thorburn D, Janssen HL et al. (2019). Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. Journal of Hepatology. 71 (2): 357-365. https://doi.org/10.1016/j.jhep.2019.04.001; PMid:30980847
Hirschfield GM, Chazouillères O, Cortez-Pinto H, Macedo G, de Lédinghen V et al. (2021). A consensus integrated care pathway for patients with primary biliary cholangitis: a guideline-based approach to clinical care of patients. Expert review of gastroenterology & hepatology. 15 (8): 929-939. https://doi.org/10.1080/17474124.2021.1945919; PMid:34233565
Huang F, Pariante CM, Borsini A. (2022). From dried bear bile to molecular investigation: A systematic review of the effect of bile acids on cell apoptosis, oxidative stress and inflammation in the brain, across pre-clinical models of neurological, neurodegenerative and neuropsychiatric disorders. Brain, Behavior, and Immunity. 99: 132-146. https://doi.org/10.1016/j.bbi.2021.09.021; PMid:34601012
Işık S, Karaman M, Micili SÇ, Çağlayan-Sözmen Ş, Bağrıyanık HA et al. (2017). Beneficial effects of ursodeoxycholic acid via inhibition of airway remodelling, apoptosis of airway epithelial cells, and Th2 immune response in murine model of chronic asthma. Allergologia et immunopathologia. 45 (4): 339-349. https://doi.org/10.1016/j.aller.2016.12.003; PMid:28256288
Kim HY, Kim SU, Kwon JH, Lee JH, Yim HJ, Cheong JY. (2020). PE-028: An Exploratory, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenofovir with and without Ursodeoxycholic Acid in Patients with Hepatitis B Virus. 춘·추계 학술대회 (KASL). 1: 179-179.
Ko WK, Kim SJ, Jo MJ, Choi H, Lee D et al. (2019). Ursodeoxycholic acid inhibits inflammatory responses and promotes functional recovery after spinal cord injury in rats. Molecular Neurobiology. 56 (1): 267-277. https://doi.org/10.1007/s12035-018-0994-z; PMid:29691718
Kriegermeier A, Green R. (2020). Pediatric cholestatic liver disease: review of bile acid metabolism and discussion of current and emerging therapies. Frontiers in Medicine. 7: 149. https://doi.org/10.3389/fmed.2020.00149; PMid:32432119 PMCid:PMC7214672
Kushnir IE. (2020). Medykamentozne urazhennia pechinky: epidemiolohiia, klinichni proiavy, diahnostychni kryterii ta pryntsypy likuvannia. Zdorovia Ukrainy.«Hastroenterolohiia. Hepatolohiia. Koloproktolohiia. 1 (55): 10-12.
Lang SM, Ortmann J, Rostig S, Schiffl H. (2019). Ursodeoxycholic acid attenuates hepatotoxicity of multidrug treatment of mycobacterial infections: A prospective pilot study. International journal of mycobacteriology. 8 (1): 89. https://doi.org/10.4103/ijmy.ijmy_159_18; PMid:30860185
Laschtowitz A, de Veer RC, Van der Meer AJ, Schramm C. (2020). Diagnosis and treatment of primary biliary cholangitis. United European gastroenterology journal. 8 (6): 667-674. https://doi.org/10.1177/2050640620919585; PMid:32299307 PMCid:PMC7437077
Liu SY, Chang LW, Wang J, Xie M, Chen LL, Liu W. (2022). Ursodeoxycholic acid prevention on cholestasis associated with total parenteral nutrition in preterm infants: a randomized trial. World Journal of Pediatrics. 8 (2): 100-108. Epub 2022 Jan 6. https://doi.org/10.1007/s12519-021-00487-0; PMid:34988851
Lu R, Yan X, Fang G, Zhuang Y, Guo Let al. (2022). A molecular mechanism of UDCA engagement with GPBAR and subsequent G protein interaction revealed by scattered alanine scanning. Biochemical and Biophysical Research Communications. 600: 14-21. https://doi.org/10.1016/j.bbrc.2022.02.030; PMid:35182970
Marushko YuV, Todyka YuY. (2014). Experience using ursodeoxycholic acid in children with disorders of the colloidal composition of bile. Sovremennaya pedyatriya. 5 (61): 135-139. doi: 10.15574/SP.2014.61.135.
Mueller M, Thorell A, Claudel T, Jha P, Koefeler H et al. (2015). Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. Journal of hepatology. 62 (6): 1398-1404. https://doi.org/10.1016/j.jhep.2014.12.034; PMid:25617503 PMCid:PMC4451470
Nagral A, Adhyaru K, Rudra OS, Gharat A, Bhandare S. (2021). Herbal immune booster-induced liver injury in the COVID-19 pandemic-a case series. Journal of Clinical and Experimental Hepatology. 11 (6): 732-738. https://doi.org/10.1016/j.jceh.2021.06.021; PMid:34230786 PMCid:PMC8252698
Niu F, Xu X, Zhang R, Sun L, Gan N, Wang A. (2019). Ursodeoxycholic acid stimulates alveolar fluid clearance in LPS‐induced pulmonary edema via ALX/cAMP/PI3K pathway. Journal of Cellular Physiology. 234 (11): 20057-20065. https://doi.org/10.1002/jcp.28602; PMid:30972764
Panel CPG, European Association for the Study of the Liver. (2019). EASL clinical practice guidelines: drug-induced liver injury. Journal of hepatology. 70 (6): 1222-1261. https://doi.org/10.1016/j.jhep.2019.02.014; PMid:30926241
Patel A, Seetharam A. (2016, Dec). Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics. J Clin Exp Hepatol. 6 (4): 311-318. https://doi.org/10.1016/j.jceh.2016.10.001; PMid:28003721 PMCid:PMC5157913
Portincasa P, Di Ciaula A, Bonfrate L, Wang DQ. (2012). Therapy of gallstone disease: What it was, what it is, what it will be. World journal of gastrointestinal pharmacology and therapeutics. 3 (2): 7. https://doi.org/10.4292/wjgpt.v3.i2.7; PMid:22577615 PMCid:PMC3348960
Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. (2012). Ursodeoxycholic acid for primary biliary cirrhosis. The Cochrane database of systematic reviews. 12 (12): CD000551. https://doi.org/10.1002/14651858.CD000551.pub3; PMCid:PMC7045744
Šarenac TM, Mikov M. (2018). Bile acid synthesis: from nature to the chemical modification and synthesis and their applications as drugs and nutrients. Frontiers in Pharmacology. 9: 939. https://doi.org/10.3389/fphar.2018.00939; PMid:30319399 PMCid:PMC6168039
Shi Q, Yang X, Greenhaw JJ, Salminen AT, Russotti GM, Salminen WF. (2017). Drug-induced liver injury in children: clinical observations, animal models, and regulatory status. International Journal of Toxicology. 36 (5): 365-379. https://doi.org/10.1177/1091581817721675; PMid:28820004
Simental‐Mendía M, Sánchez‐García A, Simental‐Mendía LE. (2020). Effect of ursodeoxycholic acid on liver markers: A systematic review and meta‐analysis of randomized placebo‐controlled clinical trials. British journal of clinical pharmacology. 86 (8): 1476-1488. https://doi.org/10.1111/bcp.14311; PMid:32285958 PMCid:PMC7373700
Tabrizian K, Shahramian I, Bazi A, Afshari M, Ghaemi A. (2019). Alleviating Effects of Ursodeoxycholic Acid in Children with Acute Hepatitis A Infection: A Randomized Clinical Trial. Hepatitis Monthly. 19: 7. https://doi.org/10.5812/hepatmon.86719
Takeyama Y, Sakisaka S. (2017). Bile Acids and Viral Hepatitis and Hepatocellular Carcinoma. In: Bile Acids in Gastroenterology. Tokyo: Springer: 157-168. https://doi.org/10.1007/978-4-431-56062-3_11; PMid:28378103
Tonin F, Arends IW. (2018). Latest development in the synthesis of ursodeoxycholic acid (UDCA): a critical review. Beilstein journal of organic chemistry. 14 (1): 470-483. https://doi.org/10.3762/bjoc.14.33; PMid:29520309 PMCid:PMC5827811
Trivedi PJ, Bruns T, Cheung A, Li KK, Kittler C, Kumagi T et al. (2014). Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. Journal of hepatology. 60 (6): 1249-1258. https://doi.org/10.1016/j.jhep.2014.01.029; PMid:24548531
Valamparampil JJ, Gupte GL. (2021). Cystic fibrosis associated liver disease in children. World Journal of Hepatology. 13 (11): 1727. https://doi.org/10.4254/wjh.v13.i11.1727; PMid:34904041 PMCid:PMC8637674
Wohab M, Selimuzzaman M, Chowdhury NAB. (2019). Protective effects of ursodeoxycholic acid on chemotherapy induced hepatic injury in acute leukemia patients: A study in Dhaka Shishu (Children) Hospital, Dhaka, Bangladesh. IOSR Journal of Dental and Medical Sciences. 18: 74-78.
Xiong J, Hu H, Xu C, Yin J, Liu M, Zhang L et al. (2022). Development of gut microbiota along with its metabolites of preschool children. BMC pediatrics. 22 (1): 1-11. https://doi.org/10.1186/s12887-021-03099-9; PMid:34991497 PMCid:PMC8734072
Yan T, Yan N, Wang H, Yagai T, Luo Y, Takahashi S et al. (2021). FXR-Deoxycholic Acid-TNF-α Axis Modulates Acetaminophen-Induced Hepatotoxicity. Toxicological Sciences. 181 (2): 273-284. https://doi.org/10.1093/toxsci/kfab027; PMid:33662127 PMCid:PMC8163055
Zhu L, Zhu J, Niu M, HU D, QI B. (2015). Effects of ursodeoxycholic acid on proinflammatory cytokines in children with infantile hepatitis syndrome. Chinese Journal of Pathophysiology: 1142-1144.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Modern pediatrics. Ukraine
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal “MODERN PEDIATRICS. UKRAINE” is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).
Authors transfer the copyright to the Journal “MODERN PEDIATRICS. UKRAINE” when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
